Evodenovo Inc.

Andover, MA

UEI
L17ZDJF2LJH1
CAGE
8P9P1
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
18 Dale St #7e, Andover, MA 01810, USA
Website
evodenovo.us
Founded
2020
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of small molecule therapeutics for mitigating opioid withdrawal syndrome R44DA053844 National Institute on Drug Abuse (NIH) $3,756,907
Identification of cyclic peptide antagonists of an anti-opioid g protein-coupled receptor RFA-DA-19-019 R43 phase i… R43DA053844 National Institute on Drug Abuse (NIH) $1,020,244

Quick answers

Is Evodenovo Inc. registered in SAM.gov?

Yes. Evodenovo Inc.'s SAM.gov registration is active through September 25, 2027.

What is Evodenovo Inc.'s most recent federal award?

Evodenovo Inc.'s most recent federal grant award is Development of small molecule therapeutics for mitigating opioid withdrawal syndrome (R44DA053844), from National Institute on Drug Abuse (NIH), on April 15, 2022.

On GovTribe

See Evodenovo Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login